- Home
- PKG vs RPRX Comparison
PKG vs RPRX Comparison
Compare PKG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PKG | RPRX |
|---|---|---|
| Founded | 1867 | 1996 |
| Country | United States | United States |
| Employees | 13600 | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7B | 25.9B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PKG | RPRX |
|---|---|---|
| Price | $253.08 | $59.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $232.38 | $51.40 |
| AVG Volume (30 Days) | 662.9K | ★ 2.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.31% | 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.91 | 0.67 |
| Revenue | ★ $8,989,300,000.00 | $2,378,193,000.00 |
| Revenue This Year | $13.32 | $38.63 |
| Revenue Next Year | $4.61 | $4.73 |
| P/E Ratio | $132.13 | ★ $87.66 |
| Revenue Growth | ★ 7.23 | 5.06 |
| 52 Week Low | $189.03 | $34.63 |
| 52 Week High | $256.44 | $59.72 |
Technical Indicators
Market Signals| Indicator | PKG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.88 | 63.63 |
| Support Level | $198.67 | $54.95 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 7.99 | 1.30 |
| MACD | 2.41 | 0.09 |
| Stochastic Oscillator | 84.96 | 92.50 |
Price Performance
Historical ComparisonAbout PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.